Investment
Features
FeesSafety
Academy
More
Pluang+

Compare abrdn Income Credit Strategies Fund (ACP) vs Heron Therapeutics Inc (HRTX) Price & Performance

abrdn Income Credit Strategies FundTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

abrdn Income Credit Strategies Fund vs Heron Therapeutics Inc — how do they compare? abrdn Income Credit Strategies Fund trades at $5.15 (market cap $641.16M), while Heron Therapeutics Inc trades at $0.34 (market cap $61.47M). The key difference: abrdn Income Credit Strategies Fund is far larger — about 10.4× Heron Therapeutics Inc's market cap, and abrdn Income Credit Strategies Fund pays a 18.2% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.

ACPHRTX
Market Cap
$641.16M$61.47M
Sector
FinancialsHealth
52-Week High
$5.98$1.49
52-Week Low
$5.01$0.32
Dividend Yield
18.2%
Enterprise Value
$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

abrdn Income Credit Strategies Fund

ACP trades at $5.14, up 1.18% today, with a neutral technical signal and bearish moving averages. The stock shows strong profitability with a net income margin of 95.31% and a low P/E of 7.74, though revenue declined to $42.46M in 2025 from $79M in 2024. Recent news highlights dividend declarations and a Seeking Alpha downgrade citing distribution sustainability concerns.

The outlook is mixed: attractive valuation and high dividends offer income appeal, but revenue volatility and high leverage pose risks. Analyst sentiment is cautious due to unsustainable distribution rates and tight credit spreads, requiring careful monitoring of earnings and credit conditions for future performance.

Heron Therapeutics Inc

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About abrdn Income Credit Strategies Fund

abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.

Read more on ACP

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX